ARTICLE | Clinical News
BG-12: Completed Phase III enrollment
December 14, 2009 8:00 AM UTC
Biogen Idec completed enrollment of >1,400 patients in the international Phase III CONFIRM trial comparing 240 mg of oral BG-12 given twice or thrice daily vs. placebo. The study also includes an arm ...